INNOVATE Swings to Profit as DBM Global Sale Reshapes Portfolio
The diversified holding company posted $46.3 million in quarterly adjusted EBITDA, nearly tripling from a year earlier, while agreeing to sell its largest operating unit for $650 million.
INNOVATE Corp. (VATE), the diversified holding company, agreed to sell its DBM Global subsidiary to IES Holdings for $650 million in cash and stock, a deal that strips out the infrastructure unit responsible for the bulk of the company's recent revenue surge and marks a decisive pivot toward a leaner corporate structure.
The transaction, announced alongside second-quarter results, values DBM Global at a moment of peak performance. The subsidiary posted record quarterly revenue of $414.0 million, up 77.6% from $233.1 million a year earlier, accounting for nearly all of INNOVATE's consolidated $421.6 million in second-quarter revenue. INNOVATE, which owns roughly 91.21% of DBM Global, expects to receive approximately $453 million in cash, 215,487 shares of IES common stock valued at $140 million, and $35 million tied to a Section 338 tax election. The company said the proceeds would go toward reducing debt.
The divestiture caps a period in which INNOVATE's financials swung sharply into the black. Consolidated second-quarter net income reached $10.4 million, reversing a $22.0 million net loss in the same quarter of 2025, while diluted earnings per share turned positive at $0.71 compared with a loss of $1.67. For the first half of 2026, the net loss narrowed to $6.8 million from $46.8 million a year earlier. Adjusted EBITDA nearly tripled to $46.3 million in the quarter from $15.7 million, and first-half adjusted EBITDA climbed 188.2% to $66.0 million.
Those gains were powered almost entirely by DBM Global's infrastructure business, which raises the central question of what INNOVATE will look like after the sale closes. The company is also divesting a controlling interest of roughly 75% in its Broadcasting segment to CONX Corp., retaining about 25% through HC2 Holdco following Broadcasting's refinancing. Together, the two transactions would leave INNOVATE without the two operating units that generated the overwhelming majority of its reported revenue.
What remains is a smaller portfolio anchored by life sciences and technology assets. MediBeacon, the company's medical-technology subsidiary, received a nomination for the 2026 Prix Galien USA Best Medical Technology award for its TGFR System, a recognition that signals external validation of the unit's product pipeline even as it has yet to contribute meaningfully to consolidated revenue.
DBM Global's standalone financial strength was underscored by its declaration of a $12 million cash dividend, or $3.12 a share, payable August 3, 2026, with INNOVATE expecting to receive approximately $11 million as the largest stockholder. That distribution, combined with the anticipated sale proceeds, gives INNOVATE a near-term cash infusion that management has earmarked for balance-sheet repair.
The first-half revenue trajectory tells the story of how quickly the growth engine built: consolidated revenue for the six months ended June 30 reached $786.4 million, up 52.3% from $516.2 million in the comparable 2025 period. Nearly all of that expansion came from DBM Global's infrastructure contracts, a concentration that made the business both the driver of INNOVATE's turnaround and the logical candidate for monetization.
With the DBM Global and Broadcasting transactions pending, INNOVATE faces the task of demonstrating that its remaining assets — including MediBeacon's nascent medical-device franchise — can sustain investor attention once the infrastructure cash register stops ringing inside the consolidated income statement.